Our Science • Olokizumab

Clinical Study Information - olokizumab

Disease area studied	Abbreviated title	Phase	Study ID	Registry database	Publication (if available)
Crohn's Disease	A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease	Phase 2	CD0001 Terminated	NCT01635621 2011-002517-11
Rheumatoid Arthritis	Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy	Phase 2	RA0056 Completed	NCT01242488 2010-020839-39	Genovese, M. C. et al. Ann Rheum Dis;2014;73;9;1607-1615
Rheumatoid Arthritis	Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056	Phase 2	RA0057 Completed	NCT01296711 2010-022224-77
Rheumatoid Arthritis	Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy	Phase 2	RA0083 Completed	NCT01463059	Takeuchi, T.et al. Mod Rheumatol;9-10-2015;1-9
Rheumatoid Arthritis	The Long-term Safety and Efficacy of Olokizumab (CDP6038) With Active Rheumatoid Arthritis	Phase 2	RA0089 Completed	NCT01533714

Our Company